FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 163 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Understanding the Risk of Second Cancers After CAR T-Cell Therapy August 13, 2024 New Type of Chemotherapy Bypasses Healthy Cells to Decrease Negative Side... December 5, 2019 First-Line Serplulimab in Combination with Chemotherapy Improves Survival in Patients with... February 14, 2023 ΥΓΡΗ ΒΙΟΨΙΑ: ΤΟ ΜΕΛΛΟΝ ΣΤΗ ΔΙΑΓΝΩΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ November 26, 2018 Load more HOT NEWS EMA Recommends Extension of Indications for Lorlatinib FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence What can elephants teach us about cancer?
